During the item generation and discussion and clarification phases, the experts identified 14 distinct challenges: costs, supply challenges, lack of evidence, polypharmacy, barriers to prescription, lack of knowledge, adherence concerns, aversion to injection therapy, clinical inertia, titration needs, perceived health state, fear of adverse effects, lack of clinical guideline recommendations, and lack of measurable outcomes to guide therapy
The weight regain observed after the discontinuation of currently approved GLP-1 and GIP/GLP-1 receptor agonists represents an unmet need for anti-obesity regimens with sustained efficacy
Erica Oberg's affordable telehealth weight loss program is an incredible accomplishment worth celebrating
Research has demonstrated that non-diabetic patients using Ozempic can lose an average of 10-15% of their body weight over a year
GLP-1 medications work in part by slowing down stomach emptying, leading to increased feelings of fullness
Contrave is an oral medication targeting cravings and emotional eating through brain pathways, while Ozempic is a weekly injection that mimics gut hormones to promote satiety and slow digestion